AgingResearch.NewsJoin free

CD57+ GRZB+ EMRA positivity

Biomarker

1 paper1 finding

  • Humans1

Associations

1

Six-month non-response to anti-PD-1/PD-L1 therapy

upin humans1

1 study

  1. CD57+ GRZB+ EMRA positivity is associated with six-month non-response to anti-PD-1/PD-L1 therapy in humans.

    “Using a 10% cut-off to define positivity, the six-month non-response tends to be associated with the CD57+ GRZB+ EMRA positivity (p = 0.097).”

    Humanscancer; CD57+ GRZB+ EMRA positivity defined using a 10% cut-offsix months

    CD57⁺ EMRA CD8⁺ T cells in cancer patients over 70: associations with prior chemotherapy and response to anti-PD-1/PD-L1 therapy

    Immunity & ageing : I & A27 Dec 2024

Latest

Related